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MRI breast with diffusion
imagingAbstract Background: Breast cancer is the most common cancer affecting females worldwide,
patient who present with late stage disease, will be treated initially with neoadjuvant chemotherapy
to downstage the disease.
Aim: To evaluate the ability of mammography, US and MRI in assessment of residual tumor and
the real extent of the disease after neoadjuvant chemotherapy.
Methods: Thirty patients proved with locally advanced breast cancer and received neoadjuvant
chemotherapy. All patients underwent mammograms, US, MRI of both breast before and after
3 cycles chemotherapy. Results at end of treatment mammography detect 20 operable lesions rang-
ing size (3–9.5 cm) with mean 5.7 cm. Ultrasound detect 30 lesions ranging size (2–6.8 cm) with
mean size 2.75 cm. MRI detected 30 lesions ranging size (1.8–7.4 cm) with mean 3.5 cm. Mammog-
raphy overestimated the actual size of residual tumor in 16 cases (80%) and underestimated the size
in 4 cases (20%). US overestimated the actual size in 6 (20%), underestimated size in 22 lesions
(73.3%). MRI overestimated the actual size in 20 lesions (66.7%), underestimated in 7 lesion
(23.3%).
Conclusion: MRI is accurate than mammography and ultrasound in detection the actual patho-
logic size of cancer breast and also in predicting the residual disease after neoadjuvant chemother-
apy.
 2014 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier
B.V. All rights reserved.ed.
246 M. Hamisa et al.1. Introduction
Breast cancer is one of the most common cancer that affect
females worldwide and it affect about 25% of all cancers in
women (1). Early stage breast cancer is typically treated surgi-
cally and then followed by post operative chemotherapy and
radiotherapy to kill any residual malignant cells. While in late
stage disease (as in cases with locally advanced breast cancer)
will be treated with neoadjuvant chemotherapy initially to
downstage the disease and then followed usually by surgery
and post operative therapies (2).
Neoadjuvant chemotherapy is used in patients with pri-
mary breast cancer, and the aim is downsizing of tumor
and down staging of disease to increase the chances for
breast-conserving surgery and also for treating occult micro
metastatic disease. Neoadjuvant chemotherapy gives about
(70–98%) clinical response rates and this lead to patholog-
ically complete response in subgroup of patients (3–34%)
(3).
Different modalities have been used to monitor the response
of neoadjuvant chemotherapy include mammography, breast
ultrasound and recently magnetic resonance imaging (4).
Mammography is the ‘‘gold standard’’ in evaluation of
the breast, It is the primary imaging modality for cancer
breast screening and diagnosis and it is one of the non-inva-
sive predictors of the actual size of the primary cancer
breast (5).
Breast ultrasound has the most important adjunct with
mammography for diagnosis of breast cancer (6). And now
it become superior in the assessment of size of the breast can-
cer and also for monitoring the response of neoadjuvant che-
motherapy (7). Ultrasound can differentiate whether the
palpable area corresponds to breast mass or to normal breast
tissue. Also breast ultrasound used for characterization of
any abnormality to evaluate the need for biopsy, and this
lead to diagnosis any other tumors not seen by mammogra-
phy (8).
Magnetic resonance imaging (MRI) of the breast is now
used giving many advantages of high resolution imaging and
multi sectional used in diagnosis of breast cancer, treatment
and research (9). Also contrast-enhanced MRI is a highly sen-
sitive method for monitoring therapeutic success in cases with
extensive or recurrent carcinoma treated with neoadjuvant
chemotherapy (10).
Now MRI with DWI is used for monitoring the early
response of the breast cancer to neoadjuvant chemotherapy,
treatment with neoadjuvant chemotherapy lead to cell lysis
and loss of integrity of the cell membrane leading to increase
extracellular space and increase the diffusion of water and
hence the DWI play important role in monitoring the effective-
ness of neoadjuvant chemotherapy (11).
1.1. Aim of this study
The aim of our study was to evaluate the diagnostic ability of
different imaging modalities (mammography, breast sonogra-
phy and breast MRI) in the assessment of neoplastic residual
tissue and the ability of each imaging method in the evalua-
tion of the real extent of the disease after neoadjuvant che-
motherapy in patients affected by locally advanced breast
carcinoma.2. Patients and methods
This prospective study was done through one year from June
2012 to June 2013. Thirty female patients, with an age range
between 28 and 67 years (mean 50 years) proved to be locally
advanced breast cancer.
Patients enrolled in our study were referred from a Cancer
Center and a clinical oncology department to the Diagnostic
Radiology Department in our university.
On mammogram, we detected 26 nodular opacities and 33
masses on US; however, 31 masses were only detected on MRI.
In all cases, breast cancer was diagnosed using FNAC and/
or true cut biopsy performed under clinical or sonographic
guidance.
Inclusion criteria:
All patients proved to have locally advanced breast cancer
Stage III,
– IIIA T3 with any N/N2 with any T (T1–T3),
– IIIB T4a skin, T4b chest wall, T4 (a + b) & T4d (inﬂamma-
tory breast cancer),
– IIIC N3 with any T.
Exclusion criteria:
– Pregnant or lactating female patients,
– Metastatic breast cancer patients,
– Patients with clinically signiﬁcant cardiac arrhythmia or
congestive heart failure.
Patients included in the study have been subjected to the
following:
 Full history taking,
 Clinical examination,
 Laboratory tests: included complete blood picture, liver
function tests and renal function tests,
 Radiological and Imaging procedures (assessing clinical
and radiological response) including:
2.1. Mammographic examination
Bilateral mammography was performed for all the patients
and included routine craniocaudal and mediolateral oblique
views of the breasts and whenever indicated spot or global
magniﬁcation views over the area of interest. Mammographic
examination is underwent using (GE senographe DMR) Four
features were speciﬁcally assessed in each mammographic
examination for each breast: nodular opacity, microcalciﬁca-
tions, architectural distortion and asymmetric density.
2.2. Ultrasound examination
Bilateral whole breast ultrasound was performed using (SIE-
MENS Sonoline G60) ultrasound systems, with a 7 MHz
superﬁcial liner small parts transducer. Survey systematic scan-
ning was done in sagittal and transverse planes and in other
planes whenever necessary according to the long axis of the
mass lesions were measured in both longitudinal and
transverse planes to obtain three diameters. For those tumors
Fig. 1 A 41-year-old female patient was presented with large left breast lump associated with nipple retraction and pathological proved
ductal carcinoma with metastatic lymph nodes show poor therapeutic effect. (A) CC, MLO views of left breast before neoadjuvant therapy
show large ill-deﬁned irregular mass with retracted nipple, after therapy show regression of the size of the mass. (B) US of left breast show
no signiﬁcant change in the size of the mass, became more hypoechoic. (C) Pulsed and Color Doppler of left breast lesion before
chemotherapy, the mass was hyper vascular. Pulsed Doppler assessment revealed high peak systolic velocity (PSV) of 81.3 cm/s and
resistive index (RI) = 0.45. (D) US of left axilla show enlarged left axillary lymph nodes. (E) MRI (Axial T1WI) of both breasts post
Gd-DTPA administration. Show no signiﬁcant change in the size or morphology of the mass.
Role of mammography, US and MRI in residual tumor assessment 247which were characterized by strong posterior shadowing, and
in which the posterior border of the lesion was not accessible,
tissue harmonic images were helpful as it decreased noisy and
better penetration & resolution (Fig. 1).
2.3. Additional ultrasound techniques
Color and power Doppler assessment were done to assess the
vascularity of the lesion.
2.4. Magnetic resonance imaging
Breast MRI was performed with a 1.5 T High Signal MRI
unit. Patients were studied in the prone position with dedicated
bilateral breast surface coils.The entire breast was imaged before and four times imme-
diately after manual intravenous injection of 0.1 mg of Gd-
DTPA/kg of body weight (Magnevist: Schering Berlin, Ger-
many) at 1, 2, 4 and 6 min.
We took all sequence (T1, T2, fat suppression sequences,
T1 with IV contrast). The post-processing procedures included
digital image subtraction, and Multiplanar Reconstruction
(MPR). Morphology (shape, border characteristics) and size
of any mass were recorded. Enhancement of the mass lesion
and curve of enhancement was done to detect the pattern of
enhancement. Associated pathological axillary lymph nodes
were also recorded and measured. Lymph nodes reported as
larger than 1 cm, matted, or exhibiting loss of fatty hilum,
thickened cortex, or irregular node contour were considered
pathologic (see Fig. 2).
Fig 1. (continued)
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Only four randomized patients were subjected to additional
diffusion-weighted magnetic resonance imaging with MRI(DW-MRI) which was performed using single shot echoplanar
imaging technique. Spectral fat saturation was used to exclude
chemical shift artifact. Qualitative assessments by different b
values (0, 300, 600, 1000), and quantitative assessment, by
Fig. 2 A 54-year-old female patient presented with left breast lump with nipple retraction. (A) CC, MLO views of Left breast show that
there is reduction in the size and density of the mass measuring 4.5 cm after therapy, it measured before therapy 6 cm. (B) US of the left
breast the mass relatively become smaller in size, it measured before the treatment 5.3 · 3.2 cm and become after treatment 5 · 3 cm, the mass
was markedly hypoechoic in internal texture with a strong posterior acoustic shadowing. (C) US of the left axilla before therapy in which
multiple enlarged axillary lymph nodes were noted with the largest lymph node measuring 1.3 · 1.2 cm. (D) Pulsed Doppler of the left breast
lesion post chemotherapy revealed a peak systolic velocity (PSV) of 53.4 cm/s and (RI) 0.90. (E) MRI (axial T1WI) of both breasts post Gd-
DTPA administration. No signiﬁcant change in the size of the mass before and after therapy was seen and it still measured about 5 · 3 cm.
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lesion. Image interpretation started by conventional breast
MRI. The dynamic scan was performed at ﬁrst and if a lesion
was visualized in the dynamic scan, it has to be identiﬁed in the
corresponding slice of the diffusion weighted images.
Tumor response to chemotherapy was assessed by compar-
ing the three imaging ﬁndings during the treatment regimen;
the response to treatment at the time of surgery was taken as
an end-point according to the response evaluation criteria in
solid tumors (RECIST).
 Histopathological examination of the tumor size was used
as the gold standard for those patients who were eligible
for radical breast surgery and was compared with tumor
measurements from mammography, US and MRI at the
end of treatment.
All patients received neoadjuvant chemotherapy treatment.
Twenty-ﬁve patients had undergone radical surgery at the endof treatment. The clinical features of locally advanced breast
cancer included tumors greater than 5 cm (T3), ﬁxation of
the tumor to the skin or chest wall (T4), skin edema, skin
ulceration, satellite nodules or inﬁltration, large (>2.5 cm)
or ﬁxed/matted axillary lymph nodes (N2), supraclavicular
lymphadenopathy or arm edema (12).
All patients received 3 cycles of Farmorubicin based regi-
mens induction chemotherapy:
– Fec-Epidoxorubicin (60 mg/m2), Cyclophosphamide
(500 mg/m2), Fluorouracil (500 mg/m2).
– Tec-Taxol (135 mg/m2), Taxotere (75 mg/m2) every
3 weeks.
The maximum dimension of the lesion or lesions corre-
sponding to the known malignancy was measured. All of these
techniques were performed before and respectively after 3
cycles of neoadjuvant treatment. The imaging ﬁndings were
correlated with the pathologic ﬁndings after surgery.
Fig 2. (continued)
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methods, patients were subdivided into 2 main groups.
1. Responders:
– Complete response (CR): no radiological evidence of
residual tumor.– Partial response (PR): reduction in size of the tumor
more than 30%.
2. Non responders:
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appearance of new lesions.After surgery, breast specimens were handled according to the
hospital routines. The results of the detailed post-operative gross
and microscopic report were compared to the last imaging ﬁnd-
ingswhichwere performed 15–21 days prior to surgery (seeFig. 3).
3. Results
Our study included 30 female patients with pathologically
proven locally advanced breast cancer which included the. 3 A 62-year-old female patient was presented with redness and
cinoma with infra clavicular LN metastasis. No appreciable therapeu
re is large ill deﬁned dense area with no signiﬁcant change after the
y duct ectasia of the left breast. (C) Dynamic MRI curve of the lesio
ore and after NACT showed a non mass enhancing lesion with ede
ast lesion showed a restricted diffusion of the left breast upper outer
o intense in the ADC map.following, 28 patients with stage IIIA {T3 with any N
and/or N2 with any T (T1–T3)}, 1 patient with stage IIIB
{T4a skin, T4b chest wall and T4 (a + b), T4d (inﬂamma-
tory breast cancer)} and 1 patient with stage IIIC {N3 with
any T}.
Twenty-seven patients had invasive duct carcinoma,
Two patients had invasive lobular carcinoma and one
patient had mixed invasive duct and lobular carcinoma.
All operable patients had modiﬁed radical mastectomy. The
ﬁnal mammography, US and MRI abnormality were
measured and correlated with the pathology for the operable
group.edema of the left breast pathological proved a lymphatic invasion
tic effect was seen. (A) CC, MLO views of the left breast show that
rapy. (B) US of the left breast. No signiﬁcant change was seen but
n showed delayed washout. (D) MRI (axial T1WI) post Gd-DTPA
ma and increased skin thickness, no response. (E) DW of the left
quadrant lesion, hyper intense in the axial b-value (600 s/mm2) and
Fig 3. (continued)
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Four features were speciﬁcally assessed in each mammo-
graphic examination for each breast: nodular opacity, micro-
calciﬁcations, architectural distortion and asymmetric density.
At the baseline, there are 26 lesions ranging in size (longest
diameter) from 3.0 cm to 10.0 cm with a mean of 6.1 cm. After
3 cycles of chemotherapy, the lesions ranged in size from 3 cm
to 9.5 cm with a mean of 5.7 cm.
After 3 cycles of chemotherapy, micro calciﬁcations became
fainter in 2 patients, 2 became more condensed and 3 of them
showed the same appearance, 10 of asymmetries decreased in
size and 9 of them showed the same appearance. In 6 patients
with architectural distortion at the baseline, 3 of them showed
regression in architecture distortion while the other three cases
showed the same appearance Table 1.After 3 cycles of chemotherapy, mammography demon-
strated PR in 6 lesions (20%), SD in 12 lesions (60%), PD in
2 lesions (20%) and 6 lesions became non measurable as
regards size of the lesion (Table 2).
3.2. Ultrasound
At the baseline, ultrasound was able to detect 33 masses rang-
ing in size (longest diameter) from 2.5 to 8 cm with a mean of
3.9 cm.
After 3 cycles of chemotherapy, US detected 30 masses,
demonstrated CR in 1 lesion (3%), PR in 16 lesions (49%),
SD in 9 lesions (27%), PD in 5 lesions (15%) and 2 lesions
(6%) became no longer measurable by US either too ill deﬁned
with inﬁltrating outline, too deep or masked by signiﬁcant
breast edema secondary to chemotherapy effect (Table 3).
Fig 3. (continued)
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At the baseline, MRI was able to detect 31 breast lesions rang-
ing in size (longest diameter) from 2 cm to 8.1 cm with a mean
size of 4.2 cm. After 3 cycles of chemotherapy, 1 lesion showed
complete remission with the remaining lesions ranging in size
from 1.8 cm to 7.4 cm with a mean of 3.5 cm.
After 3 cycles of chemotherapy, MRI demonstrated CR in 1
lesion (2.4%), PR in 18 lesions (35.7%), SD in 9 lesions
(54.8%) and PD in 3 lesions (7.1%) (Table 4).3.4. DW MRI
Four patients underwent (DW) magnetic resonance (MR)
imaging with an apparent diffusion coefﬁcient (ADC) map,
patients were classiﬁed as responders and non responders.Our result shows that the cutoff of ADC with which to dif-
ferentiate between responders and non responders was
1.17 · 103 mm.
Two patients considered responders had ADC values of
(1.299 · 103 mm2/s) and (1.305 · 103 mm2/s) (1.036 ·
103 mm2/s) and (1.102 · 103 mm2/s). The other two patients
considered non responders hadADC values of (1.036 ·
103 mm2/s) and (1.102 · 103 mm2/s) (Table 5).
Twenty-ﬁve patients, all of them received chemotherapy
and were ﬁnally considered operable and eventually subjected
to radical mastectomy. Four out of the 5 inoperable cases
received hormonal treatment and the ﬁfth case received
radiotherapy. The ﬁnal mammography, ultrasound and MRI
abnormality were measured as the greatest dimension of the
breast lesion/lesions at the end of treatment.
At the end of treatment, mammography was able to detect
only 20 operable lesions ranging in size from 3 cm to 9.5 cm
Table 1 Mammography features at the baseline and after chemotherapy.
Number at baseline Response after 3 cycles
Regressive Stationary Progressive
Nodular opacity 26 6 12 2
Microcalciﬁcations 7 2 3 2
Asymmetric densities 19 10 9 0
Architectural distortion 6 3 3 0
Total (N) of features 58 (100%) 21 (40%) 27 (52%) 4 (8%)
Table 5 DW MRI response measurement according to the
ADC value.
Number of cases Responders Non responders
>(1.17 · 103 mm2/s) <(1.17 · 103 mm2/s)
Total (4) 1.299 · 103 mm2/s 1.036 · 103 mm2/s
1.305 · 103 mm2/s 1.102 · 103 mm2/s
2 patients 2 patients
Table 6 Comparison between the major diameters of opera-
ble patients regarding mass size before and after NACT within
different imaging methods.
MAMMO US MRI Pathology
Pre-NEC
Range (cm) 3.0–10.0 2.5–8.0 2.0–8.1 NA
Mean (cm) 6.1 3.9 4.2 NA
Post-NEC
Range (cm) 3–9.5 2.0–6.8 1.8–7.4 1.5–7.0
Mean (cm) 5.7 2.75 3.5 3.3
Table 7 Correlation of mass measurements obtained by
imaging after NACT compared with pathological
measurements.
Mammography US MRI
Pearson correlation 0.223 0.576 .936
P value 0.03 0.001 <0.001






Underestimation 4 (20%) 22 (73.3%) 7 (23.3)
Equal (0.0%) 2 (6.7%) 3 (10.0)
Overestimation 16 (80%) 6 (20%) 20 (66.7%)
Total 20 30 30
Table 3 Response measured by ultrasound during
chemotherapy.
Grade of response After 3 cycles
Responders CR 1 (3%)
PR 16 (49%)
Non-responders SD 9 (27%)
PD 5 (15%)
Not measurable 2 (6%)
Total 33 (100%)
Table 2 Response measured by mammography during
chemotherapy as regards size of the lesion.
Grade of response After 3 cycles
Responders CR 0 (0.0%)
PR 6 (20.0%)
Non-responders SD 12 (60.%)
PD 2 (10.0%)
Not measurable 6 (10.0%)
Total 20 (100%)
Table 4 Response measured by MRI during chemotherapy.
Grade of response After 3 cycles
Responders CR 1 (3%)
PR 18 (58%)
Non-responders SD 9 (29%)
PD 3 (10%)
Not measurable 0 (0%)
Total 31
254 M. Hamisa et al.with a mean size of 5.7 cm. Ultrasound was able to detect 30
breast lesions ranging in size from 2 cm to 6.8 cm with a mean
size of 2.75 cm. MRI detected 30 breast masses ranging in size
from 1.8 cm to 7.4 cm with an a mean size of 3.5 cm. The
results were ﬁnally correlated with the pathological measure-
ments. Pathological specimens revealed 30 breast masses rang-
ing in size from 1.5 to 7.0 cm with a mean diameter of 3.3 cm.
Histological measurement of the tumor size was used as the
gold standard for those patients who were eligible for radical
breast surgery and was compared with tumor measurements
from mammography, US and MRI at the end of treatment
(Table 6).
The following (Table 7) demonstrates the correlation
between themammography, US andMRI ﬁnal mass and lymph
node size to the ﬁnal pathological size. Pearson correlation>0.5
and P-value <0.05 is considered to be statistically signiﬁcant.
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the residual tumor in 16 out 20 cases (80%) by 0.5–5.0 cm
(average 2.6 cm) and underestimated the size in 4 out 20 cases
(20%) by 0.5–2.0 cm (average 1.25 cm). Mammography, there-
fore, did not give the actual tumor size in any lesion. US over-
estimated the actual pathology size in 6 out of 30 lesions (20%)
by 0.1–1.0 cm (average 0.6 cm), underestimated the actual
pathology size in 22 lesions (73.3%) by 0.1–4.0 cm (average
1.35 cm) and gave the exact tumor size in 2 lesions (6.7%).
MRI overestimated the actual pathology size in 20 out of 30
lesions (66.7%) by 0.2–1.5 cm (average 0.57 cm), underesti-
mated the actual pathology size in 7 out of 30 lesions
(23.3%) by 0.2–1.0 cm (average 0.48 cm) and gave the exact
measurement in 3 out of 30 lesions (10.0%) (Table 8).4. Discussion
In spite of recent advances in screening mammography, how-
ever locally advanced breast cancer remains a clinical problem
(13).
Now neoadjuvant chemotherapy has an important part in
the standard treatment of patients with locally advanced breast
cancer (14).
Our study included 30 patients who had pathologically pro-
ven breast cancer and staged as locally advanced by clinical
examination and/or imaging methods.
We used the largest tumor diameter for each modality and
compared them with the maximum tumor diameter available
from the histology reports. The same method was used by sev-
eral studies including those by Rieber et al. (2002) (15), Mar-
tincich et al. (2004) (16), Pickles et al. (2005) (2), Shoma
et al. (2006) (17), and Chen et al.(2012) (4).
In our study, mammographic data were incomplete as it
was not possible to measure the size of the tumor in 4 out of
30 patients (13.3%), the end of chemotherapy in 10 out of
30 (33.3%) patients, high parenchymal density and diffuse
edema pattern contributed for most cases.
According to Londero et al. (2004) (18), 2 out of their 15
(13.3%) patients studied were not classiﬁable by mammogra-
phy because the high breast parenchymal density did not allow
the actual identiﬁcation of the lesion in one case and the mea-
surement of the lesion in the other case.
The mammography data of Bhattacharyya et al. (2008) (19)
were also incomplete as it was not possible to measure the size
of the tumor after chemotherapy in 18 out of 32 (56.2%)
patients studied because the tumor margins were no longer
assessable.
By the end of treatment in our study, mammography was able
to detect only 20 operable lesions.Mammography overestimated
the actual pathology size of the residual tumor in 16 out of 20
lesions (80%) by 0.5–5.0 cm (average 2.6 cm) andunderestimated
the size in 4 out of 20 cases (20%) by 0.5–2.0 cm (average
1.25 cm). Mammography, therefore, did not give the actual
tumor size in any lesion. The Pearson correlation coefﬁcient
between the ﬁnalmammography tumor size andactual pathology
size was 0.223 (indicating weak correlation). The P-value was
0.03, which means a signiﬁcant difference between mammogra-
phy tumor size and actual pathology size.
Of the 16 lesions in which mammography overestimated the
amount of residual tumor, persistent microcalciﬁcations
contributed to 2 lesions and diffuse edema pattern contributedto overestimation in 14 lesions. Failure to include the
whole mass by mammography caused underestimation in 4
lesions.
Tardivon et al. (2006) (20) mentioned that usually, under
treatment, the tumor density decreases on successive
mammograms; this decrease in density cannot be measured
and even interferes with the measurements because of the
low lesion-normal tissue contrast ratio. In such cases US
may even then be more reliable.
According to Londero et al. (2004) (18), mammography
overestimated the mean diameter of the tumor by 0.64 cm.
Their calculated Pearson correlation coefﬁcient and P-value
were a value of 0.67 and 0.012 respectively.
In a study by Wright et al. (2010) (21), mammography over-
estimated the actual pathology size by and average of 1.2 cm
with a Pearson correlation coefﬁcient of 0.15. On the other
hand, the Pearson correlation coefﬁcient and P-value in a
study by Herrada et al. (1997) (22) were statistically signiﬁcant
with a value of 0.649 and 0.0169 respectively.
Yeh et al. (2005) (10) had 16 out of 31 (51.6%) lesions
underestimated by mammography as they considered 7
patients with dense breast tissue as underestimation because
there was a known tumor and mammography was unable to
detect the tumor.
In our study, ultrasound was able to detect 30 breast lesions
at the end of chemotherapy. Ultrasound overestimated the
actual pathology size in 6 out of 30 lesions (20%) by 0.1–
1.0 cm (average 0.6 cm), underestimated the actual pathology
size in 22 lesions (73.3%) by 0.1–4.0 cm (average 1.35 cm)
and gave the exact tumor size in 2 lesions (6.7%). The Pearson
correlation coefﬁcient between the ﬁnal ultrasound tumor size
and actual pathology size was 0.576 (indicating moderate cor-
relation). The P-value was 0.001, which means a signiﬁcant dif-
ference between ultrasound tumor size and actual pathology
size.
According to Herrada et al. (1997) (22) and Peintinger et al.
(2006) (23), US tends to underestimate the residual tumor size
and is actually less accurate than physical examination with a
statistically signiﬁcant Pearson correlation coefﬁcient and P-
value of 0.600.
In a study by Montemurro et al. (2005) (24), post treatment
Pearson correlation with histopathological diameter was statis-
tically signiﬁcant measuring 0.705 with a P value <0.001.
According to Yeh et al. (2005) (10), US overestimated the
amount of tumor after chemotherapy in 4 out of 31 (12.9%)
lesions and underestimated the amount of tumor in 16 out of
31 (51.6%) lesions. Their calculated P-value was statistically
signiﬁcant with a value of 0.01.
In our study, at the end of chemotherapy, MRI was able to
detect 30 breast lesions. MRI overestimated the actual
pathology size in 20 out of 30 lesions (66.7%) by 0.2–1.5 cm
(average 0.57 cm), underestimated the actual pathology size
in 7 out of 29 lesions (23.3%) by 0.2–1.0 cm (average
0.48 cm) and gave the exact measurement in 3 out of 30 lesions
(10%). The Pearson correlation coefﬁcient between the ﬁnal
MRI tumor size and actual pathology size was 0.936 (indicat-
ing strong correlation). The P-value was <.001, which means
a signiﬁcant difference between MRI tumor size and actual
pathology size.
In a study by Rosen et al. (2003) (25), MRI imaging mea-
sured the ﬁnal tumor size accurately to be within 1 cm of the
ﬁnal tumor size determined by gross histologic examination.
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included only 15 subjects, MRI imaging overestimated the
main lesion diameter by only 0.34 cm.
Several studies, Pickles et al. (2005) (2), Akazawa et al.
(2006) (27), Bhattacharyya et al. (2008) (19), Lorenzon et al.
(2009) (26), and Chen et al. (2012) (4) have shown that MR
imaging prediction of tumor response to neoadjuvant chemo-
therapy correlates well with pathology with a statistically sig-
niﬁcant Pearson correlation coefﬁcient between MR imaging
and histology ranging between 0.6 and 0.982.
Studies done by Rosen et al. (2003) (25), Wasser et al.
(2003) (28), Denis et al. (2004) (29) and Warren et al. (2004)
(30) revealed that MRI underestimated the residual disease
in 2–10% of cases, especially if the tumor shrinkage pattern
from the chemotherapy is patchy with areas of necrosis
between nests of viable tumor or tiny tumor foci scattered over
a large area.
Diffusion weighted MRI was a helpful method in assess-
ment response to neoadjuvant chemotherapy through calcula-
tion of their ADC values, post treatment patients were divided
into two groups responders and non responders according to
ADC values, the cutoff ADC differentiating responders from
non responders was (1.17 · 103 mm2/s),those whose ADC
values were above this value were considered responders and
those whose ADC values were lower than this were considered
responders.
In a study by Woodhams et al. (31) found that DW MR
imaging had at least as good an accuracy as did contrast-
enhanced MR imaging for monitoring neoadjuvant chemo-
therapy. The ADCs prior to chemotherapy did not predict
response to chemotherapy. The use of DW imaging to visualize
residual breast cancer without the need for contrast medium
could be advantageous in women with impaired renal function.
5. Conclusion
MRI is accurate than mammography and ultrasound in
detection of the actual pathologic size of cancer breast and
also in predicting the residual disease after neoadjuvant
chemotherapy.Conﬂict of interest
There is no conﬂict of interest.
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